Ann: Imugene onCARlytics Doses First Patient in IV Combination, page-109

Don't get me wrong I am happy this patient has been enrolled into oncralytics. On paper this should give them a 60% shot at a complete response. If I was in their shoes I would try to get T cell therapy and CF33, verse CF33 in mono therapy.

This company just seems confused by all it's priorities.

My sense is management are seeing better things out of Azercel and Oncralytics, with MAST moving to the back burner.

I think they're targeting Bile duct across the board along with other rare cancers without treatment. As it has its easier to enrol and qualify patients with better general health and immune systems. Plus then opens the door to phase 2 registrational trials being quicker to revenue.